(Q30245459)

12 June 2017

1 reference

title

Interpretation of the evidence for the efficacy and safety of statin therapy (English)

1 reference

12 June 2017

1 reference

9

0 references

David Preiss

object named as

David Preiss

17

0 references

Liam Smeeth

25

object named as

Liam Smeeth

1 reference

12 June 2017

27

Salim Yusuf

1 reference

12 June 2017

18

Paul Ridker

1 reference

12 June 2017

7

Roger Blumenthal

1 reference

12 June 2017

28

Richard Peto

1 reference

12 June 2017

8

John Danesh

1 reference

12 June 2017

Rory Collins

1

1 reference

12 June 2017

Christina Reith

2

1 reference

12 June 2017

Jonathan Emberson

3

1 reference

12 June 2017

Jane Armitage

4

1 reference

12 June 2017

Colin Baigent

5

1 reference

12 June 2017

Lisa Blackwell

6

1 reference

12 June 2017

David DeMets

10

1 reference

12 June 2017

Stephen Evans

11

1 reference

12 June 2017

Malcolm Law

12

1 reference

12 June 2017

Stephen MacMahon

13

1 reference

12 June 2017

Seth Martin

14

1 reference

12 June 2017

Bruce Neal

15

1 reference

12 June 2017

Neil Poulter

16

1 reference

12 June 2017

Ian Roberts

19

1 reference

12 June 2017

Anthony Rodgers

20

1 reference

12 June 2017

Peter Sandercock

21

1 reference

12 June 2017

Kenneth Schulz

22

1 reference

12 June 2017

Peter Sever

23

1 reference

12 June 2017

John Simes

24

1 reference

12 June 2017

Nicholas Wald

26

1 reference

12 June 2017

language of work or name

English

0 references

publication date

6 September 2016

1 reference

12 June 2017

1 reference

12 June 2017

volume

388

1 reference

12 June 2017

issue

10059

1 reference

12 June 2017

page(s)

2532-2561

1 reference

De testimonio: on the evidence for decisions about the use of therapeutic interventions

12 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Bias and causal associations in observational research.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

False alarms and pseudo-epidemics: the limitations of observational epidemiology.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Problems with using observational databases to compare treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Randomized trials or observational tribulations?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Saturated fat is not the major issue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Should people at low risk of cardiovascular disease take a statin?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Healthy men should not take statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statistics notes. Treatment allocation in controlled trials: why randomise?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statistics notes: blinding in clinical trials and other studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Blinding in randomised trials: hiding who got what.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Misrepresentation of statin safety evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The controversy of a wider statin utilization: why?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statin myopathy: a common dilemma not reflected in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Adjusting for non-compliance and contamination in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Choice of endpoints in antiplatelet trials: which outcomes are most relevant to stroke patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Applying results from clinical trials: tranexamic acid in trauma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Dangers of non-specific composite outcome measures in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effects of extended-release niacin with laropiprant in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Safety profile of extended-release niacin in the AIM-HIGH trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Systematic review and meta-analysis: when one study is just not enough

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Pooling research results: benefits and limitations of meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Meta-Analysis. Potentials and promise

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Non-cardiovascular effects associated with statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Pravastatin and cognitive function in the elderly. Results of the PROSPER study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

An assessment by the Statin Intolerance Panel: 2014 update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statin tolerability: In defence of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Why representativeness should be avoided

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Blood pressure lowering and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Subgroup analysis and other (mis)uses of baseline data in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Credibility of claims of subgroup effects in randomised controlled trials: systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Forest plots and the interpretation of subgroups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

An assessment by the Statin Muscle Safety Task Force: 2014 update.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Needed: pragmatic clinical trials for statin-intolerant patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Problems in the "evidence" of "evidence-based medicine"

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

External validity of randomised controlled trials: "to whom do the results of this trial apply?".

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Why we need observational studies to evaluate the effectiveness of health care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Estimating the effect of the run-in on the power of the Physicians' Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

When are randomised trials unnecessary? Picking signal from noise

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Spurious precision? Meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Commentary: we still need observational studies of drugs--they just need to be better

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Observational research, randomised trials, and two views of medical science

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statins and Musculoskeletal Conditions, Arthropathies, and Injuries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statin use and reduced cancer-related mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Discontinuation of statins in routine care settings: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Confounding control in healthcare database research: challenges and potential approaches.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

A review of uses of health care utilization databases for epidemiologic research on therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Patterns of use of hormone replacement therapy in one million women in Britain, 1996-2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Evaluating non-randomised intervention studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Hormone therapy to prevent disease and prolong life in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Hormones and heart disease in women: the timing hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Postmenopausal oestrogen and cardioprotection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Hormone replacement therapy and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Hormone replacement therapy in general practice: a survey of doctors in the MRC's general practice research framework

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The HRT controversy: observational studies and RCTs fall in line

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Breast cancer and hormone-replacement therapy in the Million Women Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Antioxidant vitamins intake and the risk of coronary heart disease: meta-analysis of cohort studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Limits of observational data in determining outcomes from cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Can Observational Data Replace Randomized Trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The Risk of Cancer in Users of Statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statins and the risk of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Use of statins and the risk of death in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The nocebo effect: patient expectations and medication side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Nonspecific side effects of oral contraceptives: nocebo or noise?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Nonspecific medication side effects and the nocebo phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The safety of statins in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

When are observational studies as credible as randomised trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Why do the results of randomised and observational studies differ?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Major lipids, apolipoproteins, and risk of vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Cholesterol, coronary heart disease, and stroke in the Asia Pacific region

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Reduced dietary salt for the prevention of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

LDL cholesterol still a problem in old age? A Mendelian randomization study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Assessing possible hazards of reducing serum cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Rapid regression of atherosclerosis: insights from the clinical and experimental literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Mouse models for atherosclerosis and pharmaceutical modifiers.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Should there be a moratorium on the use of cholesterol lowering drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Trends in lipids and lipoproteins in US adults, 1988-2010

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

30-year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Trends in serum lipids and lipoproteins of adults, 1960-2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Protocol for analyses of adverse event data from randomized controlled trials of statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Mendelian randomization: genetic anchors for causal inference in epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Are lipid-lowering guidelines evidence-based?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Drug treatment of hyperlipidemia in women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Impact of gender on statin efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Preventive health care in elderly people needs rethinking

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Pleiotropic effects of statins. - Basic research and clinical perspectives -.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Perioperative Rosuvastatin in Cardiac Surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statin treatment and reduced risk of pneumonia in patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Prior statin use is associated with improved outcomes in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Impact of statins and ACE inhibitors on mortality after COPD exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statins in COPD: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Simvastatin for the prevention of exacerbations in moderate-to-severe COPD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Simvastatin in the acute respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Rosuvastatin for sepsis-associated acute respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The knowledge system underpinning healthcare is not fit for purpose and must change

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statin-associated rhabdomyolysis: is there a dose-response relationship?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statin safety: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

SLCO1B1 variants and statin-induced myopathy--a genomewide study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Epidemiology of stroke and its subtypes in Chinese vs white populations: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Risks associated with statin therapy: a systematic overview of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statin intolerance: reconciling clinical trials and clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Adverse effects of statins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statin use and musculoskeletal pain among adults with and without arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The nocebo effect in the context of statin intolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effect of statins on skeletal muscle function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuv

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

A systematic review of statin-induced muscle problems in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

N-of-1 (single-patient) trials for statin-related myalgia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Randomized Polypill crossover trial in people aged 50 and over

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Increased creatine kinase with statin treatment may identify statin-associated muscle symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statins and cognitive function: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statin Effects on Aggression: Results from the UCSD Statin Study, a Randomized Control Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

HMG CoA reductase inhibitors and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Predictors of self-reported health-related quality of life in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Simvastatin improves the sexual health-related quality of life in men aged 40 years and over with erectile dysfunction: additional data from the erectile dysfunction and statin trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The impact of statins on psychological wellbeing: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statins and Cataracts: Reverse Causality?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Rationale and Design of the Standard Versus Intensive Statin Therapy for Hypercholesterolemic Patients with Diabetic Retinopathy (EMPATHY) Study: a Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Proof of concept, randomized, placebo-controlled study of the effect of simvastatin on the course of age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effect of statin use on acute kidney injury risk following coronary artery bypass grafting

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Dose-dependent effect of statins on the incidence of acute kidney injury after cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Preoperative statin therapy is not associated with a reduced incidence of postoperative acute kidney injury after cardiac surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effects of lowering LDL cholesterol on progression of kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Severe irritability associated with statin cholesterol-lowering drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Serum cholesterol levels and suicide: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

An assessment of statin safety by hepatologists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Lipid-modifying therapies and risk of pancreatitis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

An assessment of statin safety by neurologists.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statins and risk of polyneuropathy: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Cardiology patient page. Statin intolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Authors' reply to Huffman and colleagues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Data Resource Profile: the Survey of Health, Ageing and Retirement in Europe (SHARE)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Absolute risk of cardiovascular disease events, and blood pressure- and lipid-lowering therapy in Australia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Cardiovascular risk and statin use in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

The crux of the matter: Did the ABC's Catalyst program change statin use in Australia?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2931357-5

7 January 2021

10.1016/S0140-6736(16)31357-5

Identifiers

DOI

1 reference

12 June 2017

1 reference